How Can Evolution Impact Human Health and Medicine?

Evolution is not just something that happened to humans long ago. It actively shapes which diseases we get, how infections outmaneuver our drugs, and increasingly, how researchers design new therapies. From the mismatch between our ancient biology and modern lifestyles to the arms race between our immune systems and pathogens, evolutionary principles run through nearly every branch of medicine. Understanding these forces does not just satisfy curiosity; it changes how doctors treat cancer, how public health officials track epidemics, and how bioengineers build better drugs.

Bodies Built for a Different World

Your body was shaped by millions of years of evolution in environments where food was scarce, physical exertion was constant, and survival depended on storing energy efficiently. Those same traits now work against you. A preference for calorie-dense foods, an ability to pack on fat during times of plenty, and a metabolism tuned for scarcity all made sense when famine was a recurring threat. In the modern world of processed food and sedentary routines, those traits drive obesity, insulin resistance, and cardiovascular disease.¹ This idea, known as the evolutionary mismatch hypothesis, has become one of the most widely invoked explanations for the high prevalence of chronic diseases in wealthy countries.²

The mismatch goes beyond diet. Human eyes evolved under broad-spectrum sunlight, and growing evidence links the modern epidemic of childhood myopia to insufficient time outdoors. Research into the specific wavelengths of light that reach the eye surface outdoors suggests that children who spend more time inside, under artificial lighting, may miss protective signals that help regulate eye growth.³ Similarly, our stress responses evolved for acute physical dangers. The chronic, low-grade psychological stress of modern life activates the same threat-detection systems, and research into anxiety disorders frames them partly as evolved precautionary responses firing too readily in an environment they were not designed for.⁴

When Ancient Defenses Become Modern Diseases

Some of the clearest examples of evolution’s impact on health involve genetic variants that protect against one disease while causing another. The most famous is the sickle cell trait. Carrying one copy of the sickle cell gene provides meaningful protection against malaria, one of history’s deadliest killers. In regions where malaria was endemic, people with this trait survived and reproduced at higher rates, pushing the gene’s frequency upward. But inheriting two copies causes sickle cell disease, a painful and life-shortening condition. The gene persists because the survival advantage for carriers outweighs the cost to those who inherit a double dose; in evolutionary terms, this is called balanced polymorphism.⁵

A similar trade-off explains why certain kidney disease variants are common among people of West African descent. Variants in the APOL1 gene protect against African sleeping sickness, a lethal parasitic infection caused by trypanosomes.⁶ But those same variants alter the protein’s shape in ways that damage kidney cells, increasing the risk of chronic kidney disease.⁷ Understanding that kidney disease risk in this population has an evolutionary origin matters medically because it shifts the research focus toward the specific molecular mechanism involved, rather than treating it as a generic risk factor.

Plagues That Reshaped Human DNA

Infectious diseases have been among the strongest selection pressures on the human genome, and the scars of past epidemics are written into our DNA. A striking example is a deletion in the CCR5 gene, called CCR5-Δ32, found at roughly 10% frequency in European populations. This deletion removes a protein that HIV uses to enter immune cells, meaning people who carry two copies are largely resistant to HIV infection. But HIV only arrived in the human population recently; the deletion was already common in Europe long before that.

One prominent hypothesis argues that CCR5-Δ32 rose to high frequency because it protected against plague. A mathematical model tracking European demography from 1000 to 1800 AD showed that repeated plague epidemics from 1347 to 1670 could plausibly have driven the deletion’s frequency to current levels, with earlier hemorrhagic fever epidemics in classical civilizations providing the initial push.⁸ The timeline is debated. Ancient DNA analysis has traced the deletion back further, finding strong evidence for positive selection on the CCR5-Δ32 haplotype between 8,000 and 2,000 years ago in Western Eurasia, earlier than plague alone would predict.⁹ Whatever the original selection pressure, the medical payoff has been real: CCR5-Δ32 became the basis for the only functional cures of HIV to date, in which patients received bone marrow transplants from donors homozygous for the deletion.¹⁰

The Immune System’s Missing Training Partners

Rates of allergies, asthma, and autoimmune diseases have climbed steeply in industrialized countries over the past century, and evolutionary thinking offers a compelling explanation. The “Old Friends” hypothesis (an updated version of the older “hygiene hypothesis”) argues that our immune systems evolved alongside specific microorganisms, including harmless bacteria, parasitic worms, and environmental microbes. These organisms helped train immune regulation, particularly the development of regulatory T cells that keep immune responses from overshooting.¹¹

Modern hygiene, antibiotics, urban living, and changes in diet have dramatically reduced our exposure to these microbial partners. The result, according to this framework, is an immune system that lacks the calibration it needs. Without adequate microbial input, the immune system becomes prone to overreacting against harmless targets like pollen, food proteins, or the body’s own tissues.¹² The idea is not that cleanliness is bad, but that the microorganisms our immune systems evolved to expect are an essential developmental input, and losing them has consequences.¹³ This perspective has practical implications: it supports research into microbiome-based therapies and even controlled reintroduction of specific organisms to treat autoimmune conditions.

Why Bacteria Keep Winning the Antibiotic Arms Race

Antibiotic resistance is evolution happening in real time, on a timescale fast enough to threaten individual patients. When bacteria are exposed to an antibiotic, the vast majority die, but any cells carrying mutations that confer even partial resistance survive and reproduce. The next generation is enriched for resistance, and after enough rounds, the drug stops working. What makes this especially dangerous is that the strength of the selective pressure matters. Bacteria evolving under strong antibiotic pressure develop not only resistance to the drug being used but also cross-resistance to several other drug classes they have never encountered.¹⁴ In some cases, though, the picture is more nuanced: bacteria that developed strong resistance to one drug class actually became more vulnerable to others, suggesting that resistance carries trade-off costs that could potentially be exploited.

Evolution also governs how virulent a pathogen becomes. The virulence-transmission trade-off hypothesis, a cornerstone of host-parasite co-evolution theory, holds that a pathogen faces a tension: replicating faster inside a host improves its chances of spreading, but killing the host too quickly cuts short the window for transmission.¹⁵ Studies of real host-parasite systems have confirmed that parasite fitness peaks at an intermediate level of replication, beyond which the cost of killing the host faster outweighs the transmission benefit.¹⁶ This has direct relevance for predicting how new pathogens will evolve after jumping into human populations.

Fighting Evolution with Evolution

If bacteria can evolve resistance, researchers have started asking: can we steer that evolution into a corner? One of the most promising approaches is phage therapy, using viruses that infect bacteria. When bacteria evolve resistance to a phage, they sometimes have to modify the same surface structures they use for other functions, including antibiotic efflux pumps. Research on the bacterium Pseudomonas aeruginosa showed that when it evolved resistance to a specific phage called OMKO1, it simultaneously became more sensitive to antibiotics, and this trade-off held up even over longer evolutionary timescales under combined phage and antibiotic pressure.¹⁷

This concept, sometimes called “phage steering,” is being developed into a deliberate therapeutic strategy. The idea is to choose phages that target bacterial surface receptors whose modification imposes a predictable cost, turning resistance into reduced virulence or renewed antibiotic sensitivity. Rather than simply trying to kill the bacteria faster, the goal is to ensure that the bacteria’s most accessible evolutionary escape route leads somewhere worse for them.¹⁸ Even when phage-resistant variants do emerge in clinical settings, these trade-offs can restore antibiotic susceptibility, keeping treatment options open.¹⁹

Evolution has also been harnessed more directly through directed evolution, a laboratory technique that mimics natural selection to improve proteins for medical use. By introducing random mutations into a protein, selecting variants that perform better, and repeating the cycle, researchers can rapidly engineer molecules with enhanced therapeutic properties.²⁰ Recent advances have combined machine learning with this process, using protein language models to predict which combinations of mutations will be most effective. One such framework achieved up to 10-fold improvements in protein function in a single round of guided evolution.²¹

Cancer as Evolution Inside the Body

Cancer is, at its core, an evolutionary process playing out inside a single person. Tumor cells accumulate mutations, and those mutations create variation. Cells that happen to grow faster, evade immune detection, or resist treatment outcompete their neighbors. Over time, this natural selection within the tumor drives increasing diversity and drug resistance.²² This is why cancers so often develop resistance to chemotherapy and why oncologists increasingly use combination therapies or adaptive dosing strategies informed by evolutionary modeling.

Comparing species offers another angle. You might expect that animals with far more cells and longer lifespans would develop cancer at much higher rates, since each cell division carries a small risk of a cancer-causing mutation. Yet they do not. This observation, called Peto’s paradox, suggests that large, long-lived species have evolved powerful cancer-suppression mechanisms that work far more effectively than anything in human cells.²³ Researchers are now expanding the search beyond just body size, looking at species that have other traits theoretically increasing cancer risk but still show unexpectedly low cancer rates, with the goal of uncovering new prevention strategies.²⁴

Why We Age and What Evolution Has to Say About It

Aging itself has evolutionary roots. The antagonistic pleiotropy hypothesis proposes that natural selection favors gene variants that boost reproduction early in life even if they cause harm later. Since reproductive success is what drives selection, genes with a “pay now, suffer later” profile spread through populations. Accumulating evidence supports this: researchers have found a strong negative genetic correlation between reproductive traits and lifespan. People with higher genetic scores for reproduction tend to have lower survivorship to age 76.²⁵ In other words, the same genetic variants that help you have more children may speed up the aging process.²⁶

If natural selection cares mostly about reproduction, why do humans live so long past their fertile years? The grandmother hypothesis offers an answer. In ancestral populations, women who remained vigorous after menopause could have boosted their own genetic legacy by helping care for grandchildren, allowing their daughters to have more children sooner.²⁷ Long postmenopausal lifespans are unique among primates, and they may have co-evolved with practices like food sharing, which made grandmothers especially valuable.²⁸ The hypothesis does not fully explain aging, but it may explain why our lineage evolved longer lifespans while female fertility still ends at ancestral ages.²⁹

The Obstetrical Dilemma

Human childbirth is famously difficult compared to that of other primates, and evolutionary biology offers a straightforward explanation for why. When our ancestors began walking upright, the pelvis had to narrow to support bipedal locomotion. At the same time, brain size was increasing, meaning newborns needed larger skulls. The result is a tight fit between the baby’s head and the birth canal, a conflict that has been called the “obstetrical dilemma.”³⁰ One proposed evolutionary solution was to deliver babies earlier in their development, which may explain why human infants are born so helpless compared to other primates.³¹ Though the hypothesis has been refined and challenged over the decades, it remains the dominant evolutionary framework for understanding why childbirth carries inherent risk in our species and why cesarean delivery rates are far higher than in any other animal.

Tracking Epidemics Through Viral Evolution

When a virus spreads through a population, it mutates along the way, and those mutations leave a trail. By sequencing viral genomes from different patients and comparing them, researchers can reconstruct the virus’s family tree and infer how and where it spread. This field, called phylodynamics, uses viral evolution as a window into epidemic behavior.³² During the COVID-19 pandemic, real-time genomic surveillance became a mainstream public health tool, allowing officials to track new variants, identify superspreader events, and estimate how quickly the virus was evolving. The same approach has been used for influenza, HIV, Ebola, and other infectious diseases. Without an understanding of how viruses evolve, this entire surveillance infrastructure would not exist.

Your Microbiome as an Evolutionary Partner

Humans are not just human. Each of us is a “holobiont,” a composite organism made up of our own cells plus trillions of microbes. The hologenome concept treats this entire community, host and microbiome together, as a unit on which natural selection can act.³³ Changes in either the host genome or the microbial community can produce variation that selection acts on, meaning your health depends as much on the interactions between you and your microbes as on the interactions between your organs.

When this partnership breaks down, it can contribute to diseases ranging from obesity and inflammatory bowel disease to neurological conditions.³⁴ The practical implication is that medicine is increasingly looking at microbiome manipulation, through dietary changes, fecal transplants, or targeted probiotics, as a way to restore an evolutionary partnership that modern life has disrupted. In this view, you are not treating a single organism when you treat a patient; you are managing an ecosystem.

How Evolution Shapes Drug Metabolism

The cytochrome P450 enzyme family is responsible for breaking down most of the drugs you take. These enzymes trace back to an ancestral gene that existed over three billion years ago, and repeated gene duplications over evolutionary time have produced one of the largest multigene families in biology.³⁵ The result is that different people carry different variants of these enzymes, which means they metabolize the same drug at very different rates. One person may clear a medication so quickly it never reaches therapeutic levels; another may break it down so slowly that a standard dose becomes toxic. This evolutionary legacy is at the heart of pharmacogenomics, the practice of tailoring drug choice and dosing to an individual’s genetic makeup. Population-level differences in P450 variants reflect ancestral diets and environmental exposures, making drug metabolism one of the most clinically tangible ways evolution touches everyday medicine.

Altitude, Adaptation, and What Genomes Reveal

Some of the most vivid examples of recent human evolution come from populations living at extreme altitudes. Tibetans have lived on the high plateau for thousands of years, and their bodies handle low oxygen in ways that differ markedly from lowland populations. A key piece of this adaptation involves variants near the EPAS1 gene, which regulates red blood cell production. In most people, low oxygen triggers a surge in red blood cells, thickening the blood and raising the risk of a dangerous condition called chronic mountain sickness. Tibetans carrying specific EPAS1 variants produce fewer red blood cells at altitude, keeping their hemoglobin levels lower and avoiding the complications of blood thickening.³⁶

The mechanism appears to work through dialing down EPAS1 activity. Research showed that Tibetan EPAS1 variants reduce gene expression, and mice engineered with a similar reduction showed blunted responses to chronic low oxygen, mirroring the Tibetan pattern. Beyond hemoglobin, the same variants are associated with reduced blood vessel constriction in the lungs, another protective adaptation.³⁷ These findings are more than anthropological curiosities. Understanding how natural selection solved the problem of chronic hypoxia could inform treatments for conditions involving low oxygen, including certain heart and lung diseases.